Business Wire

Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously

Share

Regulatory News:

Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL Vifor is supporting a growing alliance of international organizations including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland Cardiac Foundation to advocate people at risk to listen to their body, to take iron seriously and to take control over their health by seeking early diagnosis and medical help from their physician.

“We are pleased to join our patients, healthcare professionals and partners in supporting Iron Deficiency Day 2022, a call for people around the world to get informed and to understand what can happen when iron levels are not properly managed,” said Hervé Gisserot, General Manager of CSL Vifor. “We are dedicated to building awareness of iron deficiency and iron deficiency anemia, to help patients understand their symptoms, improve access and ultimately receive appropriate treatment.”

Iron deficiency and iron deficiency anemia affect one in every two chronic heart failure patients 2,3 and is associated with reduced quality of life4, reduced exercise capacity and increased risk of hospitalization5. Despite the serious consequences and high prevalence of iron deficiency, the condition remains under-recognized6.

The importance of iron for the health of heart failure patients was recently highlighted in the new whitepaper “Heart Failure, an inconvenient truth” which advocates for an extension of current heart failure management strategies to include and increasingly focus on improving quality of life. This includes early diagnosis and treatment of iron deficiency.

“Iron deficiency is a highly prevalent and serious condition among heart failure patients and has a significant impact on their quality of life,”, said Steven Macari, President of AVEC France and co-author of Heart Failure, an inconvenient truth. “It is easily diagnosed and treatable, yet many primary care professionals often overlook symptoms of iron deficiency like fatigue and breathlessness as expected comorbidities of heart failure, and it is often the proactive empowered patient who informs and suggests to be tested. It is therefore vital that we inform practitioners around the importance of diagnosing and treating iron deficiency in patients at risk, and that patient organizations inform their members.”

To learn more about the importance of early diagnosis and recognizing symptoms of iron deficiency, visit www.takeironseriously.com/check-your-symptoms . Use hashtags #TakeIronSeriously and #IDDay2022 on Twitter and LinkedIn.

Iron Deficiency Day is endorsed by multiple international organizations in the United Kingdom, Ireland, Romania, Greece, Saudi Arabia, Russia and for the first time in Slovakia.

About “Heart Failure, an inconvenient truth”

The whitepaper “Heart Failure, an inconvenient truth” is based on a pan-European survey among more than 600 heart failure patients and has been developed together with Pumping Marvellous (UK), AVEC (FR), Herzschwäche Deutschland (DE), The Patients Voice (NL), and Vintura. The aim of the paper, which was funded by CSL Vifor, is to advocate for a better quality of life in heart failure. It can be downloaded here: (https://www.viforpharma.com/sites/vifor-corp/files/White%20paper%20_heart%20failure_V10.2_Digital.pdf)

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.

Notes to Editors

Takeironseriously.com is intended to provide educational information to an international audience outside the US; it is available in 14 languages. All information on the site is intended for educational purposes only and should not be used to replace a discussion with a healthcare professional. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.

About iron deficiency

Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide7, yet despite the serious consequences and high prevalence8, it remains an under-recognized condition.

Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five9. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being10. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality10. Common symptoms include fatigue10, 12, 13 pale skin12, brittle nails12, 14, craving non-food items such as dirt, clay and ice15, and an inability to concentrate10, 16. In children, iron deficiency can significantly impair cognitive and motor development17.

The World Health Organization has published new guidelines to help the detection of iron deficiency and iron overload. These guidelines provide global, evidence-informed recommendations on the use of indicators for assessing iron status and application of the use of ferritin concentrations, an indicator of iron storage. Find more here: https://www.who.int/publications/i/item/9789240000124

References

  1. Hassan, Tamer Hasan et al. “Impact of Iron Deficiency Anemia on the Function of the Immune System in Children.” Ed. Esaki M. Shankar. Medicine 95.47 (2016): e5395. PMC. Web. 12 June 2018.
  2. Ebner N, von Haehling S. Iron deficiency in heart failure: a practical guide. Nutrients. 2013;5(9):3730-9. doi:10.3390/nu5093730.
  3. Klip IT, Comin-Colet J, Voors A a, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017.
  4. Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
  5. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
  6. Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
  7. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
  8. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.
  9. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).
  10. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
  11. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.
  12. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
  13. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.
  14. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.
  15. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
  16. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.
  17. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kioxia Receives IEEE Corporate Innovation Award9.5.2025 10:00:00 EEST | Press release

Kioxia Corporation, a world leader in memory solutions, today announced that it has received the IEEE Corporate Innovation Award from the Institute of Electrical & Electronics Engineers (IEEE), the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. This award recognizes Kioxia's outstanding contribution in the field of electrical and electronics engineering through its BiCS FLASH™ technology, a low-cost, high-capacity 3D flash memory innovation. The award ceremony was held on April 24 in Tokyo. The IEEE Corporate Innovation Award is a globally-recognized honor bestowed upon organizations that have developed innovative technologies, products or services that have made a substantial contribution to the advancement of electrical and electronics engineering. Since its inception in 1985, the award has been presented to leading electronics manufacturers and IT companies worldwide, and Kioxia is proud to be the seventh Japanese c

Suzano Reports Record First-Quarter Revenue9.5.2025 03:12:00 EEST | Press release

Suzano, the world’s largest pulp producer, announces its first quarter results for 2025 (1Q25) with record net revenue of R$11.6 billion, up 22% on the same quarter last year (1Q24). The result was driven by the exchange rates, increased pulp sales volumes from the new Ribas do Rio Pardo mill, higher paper volume and prices and the positive contribution from our paperboard mills recently acquired in the U.S. The record revenues occurred despite a series of planned downtimes in the quarter, including production lines of the Três Lagoas Unit, Mucuri Unit, and Aracruz Unit, and the Ribas do Rio Pardo Unit’s first scheduled maintenance downtime. Sales exceeded 3 million tonnes in the quarter, a rise of 12% compared to 1Q24, comprising 2.7 million tonnes of pulp and 390 thousand tonnes of paper, up 10% and 25%, respectively, on the same quarter last year. Adjusted EBITDA totaled R$4.9 billion, a 7% increase over 1Q24. Operating cash generation totaled R$2.6 billion, rising 5% on 1Q24. Net p

GC Aesthetics® Strengthens Board of Directors with Strategic Appointments8.5.2025 18:10:00 EEST | Press release

GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets is pleased to announce the appointment of Mr. Luigi Ferrari as Chairman of the Board (non-executive) and Mr. Patrick Lee as Board Director, reinforcing the company’s strategic direction and long-term growth plans. These appointments follow the renewed phase of partnership initiated in early 2024 with Hayfin Capital Management, a longstanding investor in GCA. This collaboration has brought fresh momentum to the company’s commitment to innovation, safety, and global expansion in aesthetic and reconstructive breast surgery. Luigi Ferrari, a seasoned executive and investor with a proven track record in the healthcare sector, brings deep leadership experience, commercial growth expertise and industry insight. From 2012 to 2022 he was CEO of Lima Corporate, a global medical device company in the joint replacement market, acquired then by Enovis Corp

PPG to invest $380 million to build new U.S. manufacturing facility in Shelby, N.C. for aerospace coatings and sealants8.5.2025 17:30:00 EEST | Press release

PPG (NYSE: PPG) today announced that it will invest $380 million to build a new aerospace coatings and sealants manufacturing facility in Shelby, N.C. Construction on the 62-acre site, which will initially include manufacturing and warehousing units, is set to commence in October 2025 and is expected to be completed in the first half of 2027. The 198,000-square-foot facility will enable the company to continue meeting the growing demands of the aerospace industry. It will employ more than 110 people and produce the full line of PPG’s aerospace coatings and sealants. The additional capacity of this new plant, combined with nearby transport links that improve supply chain and shipping logistics, will help improve service levels for customers. “PPG’s investment in this new manufacturing facility demonstrates the significant demand growth for our world-class technologies and our continued commitment to serving our aerospace customers,” said Tim Knavish, PPG chairman and chief executive off

WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features8.5.2025 17:00:00 EEST | Press release

WHOOP, the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and longevity. Paired with a redesigned WHOOP experience, the devices offer 14-day battery life in a sleeker, seven percent smaller form - and introduce category-defining features, including Healthspan with WHOOP Age, Heart Screener with on-demand ECG, Blood Pressure Insights, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508546933/en/ WHOOP Unveils Next Generation WHOOP® 5.0 and WHOOP® MG These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye